We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Levosimendan Administration in Neonates With Transposition of the Great Arteries

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01120106
First Posted: May 10, 2010
Last Update Posted: June 26, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Zaccaria Ricci, Bambino Gesù Hospital and Research Institute
May 6, 2010
May 10, 2010
June 26, 2012
January 2009
December 2010   (Final data collection date for primary outcome measure)
lower inotropic score in the levosimendan group [ Time Frame: Time points: from T0 (within 1 hour of intensive care unit admission) to T7 (72nd post operative hour) through T2, T3, T4, T5, T6, T7) ]
inotropic score will be calculated as: dopamine (mcg/Kg/min) * 1 + milrinone (mcg/Kg/min) * 15 + epinephrine (mcg/Kg/min) * 100.
reduction in inotropes and vasopressors requirements (calculated as inotropic score) in treated patients [ Time Frame: from intensive care unit admission after surgery to 72 post operative hours ]
inotropic score will be calculated as: dopamine (mcg/Kg/min) * 1 + milrinone (mcg/Kg/min) * 15 + epinephrine (mcg/Kg/min) * 100.
Complete list of historical versions of study NCT01120106 on ClinicalTrials.gov Archive Site
Low cardiac output syndrome (LCOS) incidence reduction in the treatment group [ Time Frame: Time points: from T0 (within 1 hour of intensive care unit admission) to T7 (72nd post operative hour) through T2, T3, T4, T5, T6, T7) ]
LCOS will be estimated by the analysis of average heart rate, mean arterial pressure, left atrial pressure, lactates and pH during the evaluated time frame
Low cardiac output syndrome (LCOS) incidence reduction in the treatment group [ Time Frame: from intensive care unit admission after surgery to 72 post operative hours ]
LCOS will be estimated by the analysis of average heart rate, mean arterial pressure, left atrial pressure, lactates and pH during the evaluated time frame
Not Provided
Not Provided
 
Levosimendan Administration in Neonates With Transposition of the Great Arteries
Perioperative Levosimendan Administration in Neonates With Transposition of the Great Arteries: Randomized Controlled Trial
Calcium sensitizer drugs such as Levosimendan may exert anti-ischemic effect in addition to positive inotropic and anti-stunning effects mediated by the opening of ATP-sensitive potassium (KATP) channels. The aim of the study is to test the myocardial protection effect of peri-operative iv infusion of Levosimendan in a cohort of neonates affected by transposition of the great arteries undergoing surgical correction by arterial switch.
Function of the myocardium of neonates with congenital heart disease may be affected by several factors in post operative phase: congenital insufficiency, cardiopulmonary bypass low perfusion, ischemima during the cross-clamp phase, low cardiac output syndrome, systemic inflammation. Furthermore, neonates have immature molecular mechanisms leading to calcium utilization inside myocytes. Calcium sensitizer drugs such as Levosimendan may exert anti-ischemic effect in addition to positive inotropic and anti-stunning effects mediated by the opening of ATP-sensitive potassium (KATP) channels. The aim of the study is to test the inodilator and myocardial protection effect of peri-operative iv infusion of 0.1 mcg/kg/min Levosimendan (without previuos bolus) in a cohort of neonates affected by transposition of the great arteries undergoing surgical correction by arterial switch.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Low Cardiac Output Syndrome
  • Drug: levosimendan
    patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min
    Other Name: simdax
  • Drug: placebo
    saline continuous infusion
    Other Name: saline
  • Active Comparator: levosimendan
    levosimendan continuous infusion at a rate of 0.1 mcg/kg<min
    Interventions:
    • Drug: levosimendan
    • Drug: placebo
  • Placebo Comparator: placebo
    saline infusion
    Interventions:
    • Drug: levosimendan
    • Drug: placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
63
September 2011
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • neonates affected by transposition of the great arteries scheduled to elective surgery

Exclusion Criteria:

  • neonates affected by transposition of the great arteries who are not scheduled to elective surgery (urgent procedures, patients older than 30 days)
Sexes Eligible for Study: All
up to 30 Days   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Italy
 
 
NCT01120106
levoTGA1
No
Not Provided
Not Provided
Zaccaria Ricci, Bambino Gesù Hospital and Research Institute
Bambino Gesù Hospital and Research Institute
Not Provided
Study Director: Sergio Picardo, MD, Head Bambino Gesù Hospital
Bambino Gesù Hospital and Research Institute
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP